RecallHawk

NAROPIN (ROPIVACAINE HYDROCHLORIDE)

FRESENIUS KABI USA

Summary

FDA approved NAROPIN (ROPIVACAINE HYDROCHLORIDE) by FRESENIUS KABI USA. NDA (New Drug) approval (Labeling) on 2022-06-28. SOLUTION, INJECTION.

Details

Source

Drug Approval

External ID

NDA020533-44

Action Date

2022-06-28

Status

Approved

Category

drug

Product Code

NDA (New Drug)

Product Description

NAROPIN (generic: ROPIVACAINE HYDROCHLORIDE), SOLUTION, INJECTION. Application: NDA020533

Context & Analysis

FRESENIUS KABI USA has 70 FDA actions in our database.

Frequently Asked Questions

How often does FRESENIUS KABI USA have FDA actions?

FRESENIUS KABI USA has 70 FDA actions in our database, including 0 recalls and 0 device clearances.

Where can I find the official FDA record?

The official record is available on FDA.gov. Search for "NDA020533-44" on FDA.gov for the full record. You can also use the openFDA API to query this record programmatically.

Want to know the moment something like this happens?

Get alerts for drug

Related Actions